Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia
This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had receive...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:dnet:digitalcsic_::9027719b642fd2efc6fa07bce70605a4 |
| Acceso en línea: | http://hdl.handle.net/10261/288789 |
| Access Level: | acceso abierto |
| Palabra clave: | Acute myeloid leukemia FLT3-ITD mutation Real-world outcomes Relapsed/refractory disease Salvage therapy |
| id |
ES_0ea5cd365979014ddeec01f4afef2ff7 |
|---|---|
| oai_identifier_str |
oai:dnet:digitalcsic_::9027719b642fd2efc6fa07bce70605a4 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemiaMartínez-Cuadrón, DavidSerrano, JosefinaMariz, JoséGil, CristinaTormo, MarMartínez-Sánchez, PilarRodríguez-Arbolí, EduardoGarcía-Boyero, RaimundoRodríguez-Medina, CarlosMartínez-Chamorro, CarmenPolo, MartaBergua, JuanAguiar, ElianaAmigo, María LuzHerrera, PilarAlonso-Domínguez, Juan ManuelBernal, TeresaEspadana, AnaSayas, María-JoséAlgarra, LorenzoVidriales, Maria BelénVasconcelos, GraçaVives, SusanaPérez-Encinas, ManuelLópez, AurelioNoriega, VíctorGarcía-Fortes, MaríaChillón, M. del CarmenLópez, Juan A.Boluda, BlancaRodríguez-Veiga, RebecaMartínez-López, JoaquínBarragán, EvaSanz, Miguel ÁngelMontesinos, PauAcute myeloid leukemiaFLT3-ITD mutationReal-world outcomesRelapsed/refractory diseaseSalvage therapyThis retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant.This study was supported by Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Valencia, Spain [CB16/12/00284].Multidisciplinary Digital Publishing InstituteCentro de Investigación Biomédica en Red Cáncer (España)Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2023202320222023info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/288789reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttp://dx.doi.org/10.3390/cancers14112817Síinfo:eu-repo/semantics/openAccessoai:dnet:digitalcsic_::9027719b642fd2efc6fa07bce70605a42026-05-22T06:33:51Z |
| dc.title.none.fl_str_mv |
Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia |
| title |
Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia |
| spellingShingle |
Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia Martínez-Cuadrón, David Acute myeloid leukemia FLT3-ITD mutation Real-world outcomes Relapsed/refractory disease Salvage therapy |
| title_short |
Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia |
| title_full |
Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia |
| title_fullStr |
Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia |
| title_full_unstemmed |
Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia |
| title_sort |
Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia |
| dc.creator.none.fl_str_mv |
Martínez-Cuadrón, David Serrano, Josefina Mariz, José Gil, Cristina Tormo, Mar Martínez-Sánchez, Pilar Rodríguez-Arbolí, Eduardo García-Boyero, Raimundo Rodríguez-Medina, Carlos Martínez-Chamorro, Carmen Polo, Marta Bergua, Juan Aguiar, Eliana Amigo, María Luz Herrera, Pilar Alonso-Domínguez, Juan Manuel Bernal, Teresa Espadana, Ana Sayas, María-José Algarra, Lorenzo Vidriales, Maria Belén Vasconcelos, Graça Vives, Susana Pérez-Encinas, Manuel López, Aurelio Noriega, Víctor García-Fortes, María Chillón, M. del Carmen López, Juan A. Boluda, Blanca Rodríguez-Veiga, Rebeca Martínez-López, Joaquín Barragán, Eva Sanz, Miguel Ángel Montesinos, Pau |
| author |
Martínez-Cuadrón, David |
| author_facet |
Martínez-Cuadrón, David Serrano, Josefina Mariz, José Gil, Cristina Tormo, Mar Martínez-Sánchez, Pilar Rodríguez-Arbolí, Eduardo García-Boyero, Raimundo Rodríguez-Medina, Carlos Martínez-Chamorro, Carmen Polo, Marta Bergua, Juan Aguiar, Eliana Amigo, María Luz Herrera, Pilar Alonso-Domínguez, Juan Manuel Bernal, Teresa Espadana, Ana Sayas, María-José Algarra, Lorenzo Vidriales, Maria Belén Vasconcelos, Graça Vives, Susana Pérez-Encinas, Manuel López, Aurelio Noriega, Víctor García-Fortes, María Chillón, M. del Carmen López, Juan A. Boluda, Blanca Rodríguez-Veiga, Rebeca Martínez-López, Joaquín Barragán, Eva Sanz, Miguel Ángel Montesinos, Pau |
| author_role |
author |
| author2 |
Serrano, Josefina Mariz, José Gil, Cristina Tormo, Mar Martínez-Sánchez, Pilar Rodríguez-Arbolí, Eduardo García-Boyero, Raimundo Rodríguez-Medina, Carlos Martínez-Chamorro, Carmen Polo, Marta Bergua, Juan Aguiar, Eliana Amigo, María Luz Herrera, Pilar Alonso-Domínguez, Juan Manuel Bernal, Teresa Espadana, Ana Sayas, María-José Algarra, Lorenzo Vidriales, Maria Belén Vasconcelos, Graça Vives, Susana Pérez-Encinas, Manuel López, Aurelio Noriega, Víctor García-Fortes, María Chillón, M. del Carmen López, Juan A. Boluda, Blanca Rodríguez-Veiga, Rebeca Martínez-López, Joaquín Barragán, Eva Sanz, Miguel Ángel Montesinos, Pau |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Centro de Investigación Biomédica en Red Cáncer (España) Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72] |
| dc.subject.none.fl_str_mv |
Acute myeloid leukemia FLT3-ITD mutation Real-world outcomes Relapsed/refractory disease Salvage therapy |
| topic |
Acute myeloid leukemia FLT3-ITD mutation Real-world outcomes Relapsed/refractory disease Salvage therapy |
| description |
This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022 2023 2023 2023 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 Publisher's version info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10261/288789 |
| url |
http://hdl.handle.net/10261/288789 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
http://dx.doi.org/10.3390/cancers14112817 Sí |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Multidisciplinary Digital Publishing Institute |
| publisher.none.fl_str_mv |
Multidisciplinary Digital Publishing Institute |
| dc.source.none.fl_str_mv |
reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC instname:Consejo Superior de Investigaciones Científicas (CSIC) |
| instname_str |
Consejo Superior de Investigaciones Científicas (CSIC) |
| reponame_str |
DIGITAL.CSIC. Repositorio Institucional del CSIC |
| collection |
DIGITAL.CSIC. Repositorio Institucional del CSIC |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869403409317101568 |
| score |
15,811543 |